Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
bizalimogene ralaplasmid (VGX-3100)
i
Other names:
VGX-3100, VGX 3100, pGX-3002, ABC-3100
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
ApolloBio, Inovio
Drug class:
HPV-16 E6 protein inhibitor, HPV-16 E7 protein inhibitor
Related drugs:
‹
Versamune HPV (1)
HB-200 (1)
BNT113 (0)
CRTE7A2-01 (0)
HB-201 (0)
HPV-T (0)
ISA101 (0)
MEDI0457 (0)
NEXI-003 (0)
RTX-321 (0)
TG4001 (0)
DPX-E7 (0)
E7 TCR-T (0)
KITE-439 (0)
axalimogene filolisbac (0)
TSC-200-A0201 (0)
Versamune HPV (1)
HB-200 (1)
BNT113 (0)
CRTE7A2-01 (0)
HB-201 (0)
HPV-T (0)
ISA101 (0)
MEDI0457 (0)
NEXI-003 (0)
RTX-321 (0)
TG4001 (0)
DPX-E7 (0)
E7 TCR-T (0)
KITE-439 (0)
axalimogene filolisbac (0)
TSC-200-A0201 (0)
›
Associations
News
Trials
Filter by
Latest
29d
VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions (clinicaltrials.gov)
P2, N=35, Active, not recruiting, AIDS Malignancy Consortium | Recruiting --> Active, not recruiting | N=80 --> 35 | Trial completion date: Sep 2029 --> Jan 2027 | Trial primary completion date: Sep 2029 --> Jan 2026
29 days ago
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
|
PD-L1 expression
|
bizalimogene ralaplasmid (VGX-3100)
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login